Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyAetna Procalcitonin (PCT) Coverage Update | OpenPa…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0771

    Procalcitonin (PCT)

    Customize your policy alerts

    Sign up for Aetna Policy 0771 alerts

    Get alerted when Policy 0771 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs when measurement of procalcitonin (PCT) is considered medically necessary or experimental/investigational for Aetna members, focusing on use to guide antibiotic initiation and discontinuation in ICU and inpatient respiratory infections and listing many indications judged investigational.

    Policy Summary
    PayerAetna
    PolicyProcalcitonin (PCT)
    Policy CodePolicy 0771
    Change TypeNo material change
    Effective DateNov 21, 2008
    Last ReviewOct 26, 2023
    Next Review DateAug 22, 2024
    Key ActionOrder PCT (CPT 84145) only when selection criteria are met to support initiating or discontinuing antibiotics in ICU patients or to guide inpatient respiratory infection management.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2FDA-cleared assays
    ICU + inpatientPrimary covered uses
    46Investigational indications
    1CPT listed
    10/26/2023Last review

    Coverage Criteria

    inv-01: Medically Necessary Indications — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Medically necessary uses: Measurement of procalcitonin (PCT) is medically necessary for initiating and discontinuing antibiotic therapy in persons in the intensive care unit and for persons with respiratory tract infections in the inpatient hospital setting to reduce antibiotic prescription rates and duration of use.

    From policy 'Medical Necessity' statement.

    inv-02: Experimental / Investigational Indications — Considered experimental/investigational for the following indications due to insufficient evidence

    Considered experimental/investigational for the following indications due to insufficient evidence:

    Experimental/Investigational indications list: PCT measurement is experimental and investigational for numerous indications including: neonatal bacterial infection; rhino‑sinusitis; bacterial meningitis; sepsis after cardiac surgery; marker/prognostic use in COVID‑19; predictor of acute kidney injury; diagnosis and monitoring of surgical infections (e.g., intra‑abdominal infection after elective colorectal surgery, peri‑prosthetic joint infection); diagnosis and prognosis of bacterial infections in persons with rheumatoid arthritis or severe acute malnutrition; diagnosis of acute pyelonephritis; diagnosis of anastomotic leakage after colorectal surgery; diagnosis of appendicitis; diagnosis of bacterial infections in individuals with systemic lupus erythematosus; diagnosis of chronic renal insufficiency; early‑onset neonatal sepsis (including culture‑positive sepsis); hypersensitivity pneumonitis; infective endocarditis; medullary thyroid carcinoma; non‑alcoholic fatty liver disease; parapneumonic pleural effusions; pancreatic necrosis; post‑operative pancreatic fistula after pancreatoduodenectomy; spontaneous bacterial peritonitis; urinary tract infection; ventilator‑associated pneumonia; differential diagnosis between bacteremia and candidemia; differential diagnosis between bacterial and viral pneumonia in community settings; differential diagnosis of infected vs non‑infected diabetic foot ulcer; differentiation of infection from inflammatory complications after HSCT; evaluation of fever of uncertain source in infants; evaluation of suspected lower respiratory tract infection or sepsis in ambulatory/ED settings; guidance of antibiotic use in COPD exacerbations and diabetic foot ulcers; management of immunocompromised individuals; prediction and prognostication indications (stroke, ARDS, TB mortality, carotid endarterectomy neurological deficits, pneumonia prediction, COPD exacerbation severity, cholangitis severity, major trauma, acute coronary syndrome, outcomes after cardiac arrest).
    Policy Summary
    PayerAetna
    PolicyProcalcitonin (PCT)
    Policy CodePolicy 0771
    Change TypeNo material change
    Effective DateNov 21, 2008
    Last ReviewOct 26, 2023
    Next Review DateAug 22, 2024
    Key ActionOrder PCT (CPT 84145) only when selection criteria are met to support initiating or discontinuing antibiotics in ICU patients or to guide inpatient respiratory infection management.
    SourceLink
    On This Page
    Coverage CriteriaCovered Indications and UsesCodingProvider Actions and Billing GuidanceFrequency Limits and Testing CadenceOrdering RequirementsNot Covered / Experimental UsesBackgroundDefinitions and AssaysEvidence Highlights and Key StudiesRevision History

    Numbered list items 1–44 in policy; additional items enumerated in document.

    inv-03: General clinical utility summary — Evidence-based findings summarized

    Evidence-based findings summarized:

    PCT diagnostic performance for sepsis: Meta-analyses report pooled sensitivity and specificity around 71%; PCT alone poorly differentiates sepsis from non‑infectious systemic inflammation.sensitivity 71%, specificity 71%

    Tang et al (meta-analysis) and UpToDate summary.

    PCT-guided antibiotic stewardship: Randomized trials suggest PCT‑guided algorithms can shorten antibiotic duration without increasing mortality in some settings (example: median antibiotic duration 6.0 vs 12.5 days in one RCT), but trials have limitations (small sample sizes, exclusions, algorithm overruling) and broader clinical utility remains uncertain.shorter median antibiotic duration reported (6.0 vs 12.5 days in one RCT)

    Nobre et al (2008) RCT and related critiques.

    Setting- and population-specific accuracy: Diagnostic accuracy varies by population: moderate-to-high for pediatric acute pyelonephritis at certain cutoffs, limited or poor accuracy for neonatal culture‑positive sepsis and variable performance in critical care and specialized populations.APN: PCT >=1.0 ng/ml improved specificity to 0.91

    Zhang et al (meta-analysis) and neonatal and ICU studies.

    inv-04: Evidence summaries — Clinical findings from the document relevant to potential coverage considerations

    Clinical findings from the document relevant to potential coverage considerations:

    Sepsis and systemic infection: Meta-analyses show elevated PCT associated with bacterial infection, but pooled sensitivity and specificity for distinguishing sepsis from non‑septic inflammation are approximately 71% each; PCT‑based algorithms did not affect mortality in analyzed trials.

    UpToDate and Tang et al meta-analysis.

    Pediatric acute pyelonephritis: Meta‑analysis in children with UTI: PCT >=0.5 ng/ml pooled sensitivity 0.86 and specificity 0.76; using 1.0 ng/ml improved specificity to 0.91 and AUROC to 0.94, suggesting 1.0 ng/ml may be preferable for APN diagnosis in pediatrics.0.5 and 1.0 ng/ml

    Zhang et al (2016) meta-analysis.

    Neonatal sepsis: Prospective multicenter neonatal study found PCT at 2 ng/ml had sensitivity 52.3% and specificity 64.5% for culture‑positive sepsis; authors concluded PCT did not reliably identify culture‑positive neonatal sepsis.2 ng/ml

    Chaurasia et al (2023).

    Community-acquired pneumonia (CAP): In adults hospitalized with CAP, PCT concentration at presentation was strongly associated with risk of needing invasive respiratory/vasopressor support (IRVS); adding PCT improved prediction of IRVS when combined with established severity scores (e.g., 1 ng/ml increase associated with ~1–2% absolute IRVS risk increase).continuous association; examples noted (per 1 ng/ml -> 1–2% absolute IRVS risk)

    Self et al (2016).

    Post-operative intra-abdominal infection after colorectal surgery: CRP outperformed PCT for detecting post‑operative intra‑abdominal infections on day 4 in one prospective study; meta-analysis found no added value of PCT over CRP for early detection to guide discharge.post-op day 3–5 comparisons

    Facy et al (2016); Cousin et al (meta-analysis).

    inv-05: Indication-specific evidence summaries — Evidence-based findings and conclusions by indication

    Evidence-based findings and conclusions by indication:

    Pancreatic necrosis: Available diagnostic studies (3 studies, 242 participants) had variable sensitivities (0.72–0.88) and specificities (0.75–1.00) with wide confidence intervals; reviewers concluded none of the tests (including PCT) were sufficiently accurate to support clinical use and further well‑designed diagnostic accuracy studies are needed.

    Cochrane review and included studies.

    Peri‑prosthetic joint infection (PJI): Meta‑analysis (18 studies) comparing IL‑6 and PCT showed IL‑6 AUC 0.93 (sens 0.83, spec 0.91) and PCT AUC 0.83 (sens 0.58, spec 0.95); PCT has a high positive likelihood ratio but inadequate negative LR (0.44), making it unsuitable as a rule‑out test and appropriate only as an adjunctive rule‑in test.

    Yoon et al (2018) meta-analysis.

    Immunocompromised patients: Limited evidence indicates PCT is elevated in bacterial infections but low in fungal infections; in transplant recipients PCT may help detect infectious complications but should not be used as the sole decision criterion and functions best as an adjunct to clinical and other laboratory data.

    Savas Bozbas et al (2016) and AHRQ research needs.

    Rhino‑sinusitis (ARS): Small randomized trials of PCT‑guided antibiotic therapy reduced antibiotic prescriptions without worse patient‑reported outcomes, but overall literature is limited and larger RCTs are needed to confirm benefit.

    Policy enumerated small RCTs; evidence limited.

    Candidemia vs bacteremia: Systematic review (16 studies) found lower PCT values in candidemia than bacteremia, but evidence was low quality and insufficiently discriminative to guide antifungal therapy; PCT should not be used alone to distinguish candidemia from bacteremia.

    Cortegiani et al (2019).

    Community-acquired pneumonia (CAP) diagnostic use: Meta‑analysis (12 studies, 2,408 patients) found PCT sensitivity 0.55 and specificity 0.76 for distinguishing bacterial from viral pneumonia; authors concluded PCT is unlikely to reliably mandate or withhold antibiotics in CAP.

    Kamat et al (2020).

    Diabetic foot ulcer: Available data do not support PCT as effective for differentiating infected versus non‑infected diabetic foot ulcers; other markers (CRP, IL‑6, fibrinogen) performed better in reported studies.

    Expert review cited in references.

    Prognostic uses (TB, trauma, post‑cardiac arrest): PCT has been associated with mortality risk in pulmonary tuberculosis and with worse outcomes after major trauma and cardiac arrest (meta‑analysis: elevated PCT within 0–48 hours associated with higher in‑hospital mortality and poor neurologic outcomes), but these findings require validation in well‑designed studies before routine clinical application.

    Osawa et al; AlRawahi; Shin et al (meta‑analysis).

    The policy text and CPT/ICD crosswalk identify specific ICD‑10 codes that are noted as not covered for CPB‑listed indications. Examples listed in the policy include A15.0–A15.9 (respiratory tuberculosis), B37.0–B37.9 (candidiasis), and C73 (malignant neoplasm of thyroid gland / medullary thyroid carcinoma). The ICD‑10 list in the document also annotates certain respiratory codes (e.g., J00‑J06.9, J20.0‑J21.9) as not covered for evaluation of suspected lower respiratory tract infection or sepsis in the ambulatory/ED setting and for use as a biomarker for rhino‑sinusitis.

    The provided evidence summaries do not state formal coverage exclusions in the cited sections. Instead, systematic reviews and guideline reviews conclude that PCT should not be relied upon alone to rule in or rule out conditions such as sepsis or infective endocarditis because pooled diagnostic performance is limited and clinical algorithms based solely on PCT did not consistently affect mortality outcomes.

    The document does not list explicit test‑level exclusions (e.g., specific assay names or methods excluded). Rather, multiple reviews noted insufficient or inconsistent evidence for routine diagnostic use of PCT across many indications (for example neonatal sepsis and other settings), implying limited utility but not enunciating test‑specific exclusions.

    A systematic review found that although PCT values are generally lower in candidemia than bacteremia, the evidence is heterogeneous and of low quality; the authors concluded that PCT should not be used as a stand‑alone tool to differentiate bacteremia from candidemia and that PCT alone is insufficient to guide antifungal therapy.

    The portions of the policy containing policy history and administrative information do not provide explicit coverage exclusions; they record review dates, effective date, and next review but do not add additional exclusion language for clinical indications.

    The policy lists numerous indications in the Experimental and Investigational section and states that measurement of PCT for these listed uses is considered experimental/investigational. As such, PCT use for the enumerated indications (for example neonatal bacterial infection, rhino‑sinusitis, bacterial meningitis, ventilator‑associated pneumonia, differential diagnoses such as bacteremia vs candidemia, and many others) is regarded in the policy as not proven and therefore not medically necessary for those purposes.

    Meta‑analyses and reviews cited in the policy indicate that PCT alone does not provide sufficient diagnostic accuracy to definitively diagnose severe sepsis or septic shock. One pooled analysis reported sensitivity and specificity near 71% each, and guideline summaries emphasize there is no single laboratory test that confirms severe sepsis or septic shock, so reliance on PCT as a single definitive diagnostic test is not supported.

    A Cochrane review of diagnostic tests for pancreatic necrosis found only three studies (242 participants) with variable sensitivities and specificities and wide confidence intervals; the authors concluded that CRP, PCT, and LDH were not sufficiently accurate to support clinical use for diagnosing pancreatic necrosis given the paucity and methodological limitations of the evidence.

    For both pancreatic necrosis and for distinguishing bacterial versus viral community‑acquired pneumonia, the policy cites evidence showing limited diagnostic performance. The Cochrane review and CAP meta‑analyses conclude that current data do not demonstrate that PCT is sufficiently accurate to guide routine clinical management for these diagnostic purposes.

    The cited administrative and policy history sections do not include explicit 'not medically necessary' statements beyond those already provided elsewhere in the policy; they record review dates and versioning without adding new clinical determination language.

    Covered Indications and Uses

    inv-53: Guide initiation and discontinuation of antibiotic therapy in ICU patients and guide antibiotic use for respiratory tract infections in the inpatient hospital setting

    Intended covered use and key contextual notes:

    ICU antibiotic stewardship: Use of PCT to guide initiation and discontinuation of antibiotics in ICU patients where algorithms and serial measurements (example: 3‑ and 5‑day assessments) are applied to reduce antibiotic duration.serial measurements at days 3 and 5 reported in trials

    Nobre et al (2008) and policy medical necessity statement.

    Inpatient respiratory tract infections: Use of PCT to guide antibiotic therapy for respiratory tract infections in the inpatient hospital setting to reduce antibiotic prescription rates and duration of use; PCT may also add prognostic information in CAP when combined with severity scores.association with IRVS risk; per 1 ng/ml increase ~1–2% absolute IRVS risk

    Policy medical necessity statement and Self et al (2016).

    inv-54: Diagnostic aid for spontaneous bacterial peritonitis (SBP) and acute pyelonephritis (pediatrics)

    Diagnostic aid evidence (limited data):

    Spontaneous bacterial peritonitis (SBP): Systematic review identified 3 studies (181 episodes) with pooled sensitivity 86% and specificity 80% for serum PCT in diagnosing SBP; authors concluded moderate‑to‑high accuracy but recommended larger prospective studies.sensitivity 86%, specificity 80%

    Su et al (2012).

    Pediatric acute pyelonephritis (APN): Meta‑analysis in children with UTI (18 studies, 831 APN patients) found PCT >=0.5 ng/ml pooled sensitivity 0.86 and specificity 0.76; using 1.0 ng/ml improved specificity to 0.91 and AUROC to 0.94, supporting diagnostic performance at specified cut‑offs in pediatrics.0.5 ng/ml and 1.0 ng/ml cutoffs evaluated

    Zhang et al (2016).

    inv-55: Assessment of bloodstream infection and sepsis in specialized populations (cancer patients, renal impairment)

    Assessment evidence in specialized populations (adjunctive use):

    Cancer patients / bloodstream infection: Pilot data in non‑neutropenic febrile cancer patients showed higher baseline PCT in bloodstream infection and decreases with effective antibiotics, suggesting PCT may help predict BSI and response to therapy; larger trials are needed.

    Shomali et al (2012).

    Renal impairment: Meta‑analysis in patients with renal impairment reported pooled sensitivity ~73% and specificity ~88% for PCT; acceptable specificity supports adjunctive rule‑in use but poor sensitivity limits rule‑out utility.sensitivity ~73%, specificity ~88%

    Lu et al (2013).

    Immunocompromised/transplant recipients: Studies indicate PCT correlates with bacterial infection in transplant recipients but should not be the sole criterion for diagnosis; use as adjunctive information is appropriate.

    Savas Bozbas et al (2016); AHRQ research needs.

    inv-56: Evaluation of suspected acute pyelonephritis in infants and children (investigational evidence supports diagnostic performance at specified cut-offs).

    Pediatric and neonatal diagnostic performance notes:

    Pediatric APN cutoffs: Meta‑analysis suggests PCT cut‑offs of 0.5 ng/ml and 1.0 ng/ml were evaluated; 1.0 ng/ml improved specificity (0.91) and AUROC (0.94) and may be a preferable threshold for diagnosing APN in children.0.5 ng/ml; 1.0 ng/ml (improved specificity)

    Zhang et al (2016).

    Neonatal sepsis limitations: Prospective multicenter neonatal study found PCT at 2 ng/ml had sensitivity 52.3% and specificity 64.5% for culture‑positive sepsis, indicating limited reliability for neonatal sepsis diagnosis at that threshold.2 ng/ml

    Chaurasia et al (2023).

    inv-57: Risk stratification in adult community-acquired pneumonia for predicting need for invasive respiratory/vasopressor support.

    Prognostic utility in CAP when combined with clinical severity scores:

    Risk stratification for IRVS in CAP: In hospitalized adults with community‑acquired pneumonia, higher PCT at presentation was associated with greater risk of needing invasive respiratory and/or vasopressor support within 72 hours; adding PCT to established severity scores improved prediction of IRVS.per 1 ng/ml increase -> ~1–2% absolute increase in IRVS risk

    Self et al (2016).

    inv-58: Peri-prosthetic joint infection (adjunctive rule‑in test); prognostication after cardiac arrest

    Adjunctive rule‑in and prognostic evidence:

    Peri‑prosthetic joint infection (PJI): Meta‑analysis indicates PCT has high positive likelihood ratio and high specificity but low sensitivity (pooled negative LR 0.44), making it useful as an adjunctive rule‑in test for PJI but not as a sole rule‑out test.

    Yoon et al (2018).

    Prognostication after cardiac arrest: Meta‑analysis found elevated PCT within 0–48 hours post‑cardiac arrest associated with higher in‑hospital mortality and poor neurologic outcomes; findings are promising for prognostication but require validation.

    Shin et al (2019).

    inv-59: Assessment of infection in immunocompromised or transplant recipients (adjunctive)

    Adjunctive use recommended; not a sole decision criterion:

    Immunocompromised and transplant recipients: PCT correlates with bacterial infection in immunocompromised and transplant patients and may be informative, but results should be interpreted with clinical assessment and other laboratory data; PCT should not be used alone for diagnosis or management decisions.

    AHRQ assessment; Savas Bozbas et al.

    inv-60: Various indications discussed in the literature cited include diagnosis and prognosis of sepsis, lower respiratory tract infections, community-acquired pneumonia, neonatal bacterial infection, surgical infections, anastomotic leakage, periprosthetic joint infection, acute pyelonephritis, and other infectious/inflammatory conditions.

    Other literature‑reported indications and contexts (evidence cited in references):

    Literature‑reported indications: Published studies and reviews discuss PCT use for diagnoses and prognostication across a broad set of conditions including sepsis, lower respiratory tract infections, community‑acquired pneumonia, neonatal bacterial infection, surgical infections, anastomotic leakage, periprosthetic joint infection, acute pyelonephritis, pleural infections, TB mortality prediction, trauma, and other infectious/inflammatory conditions; these references are cataloged in the policy bibliography but do not by themselves establish coverage beyond the stated medically necessary indications.

    References 54–115 list multiple topic‑specific studies and reviews.

    Coding

    Covered CPT Codes (when selection criteria met)CPTCovered
    84145Procalcitonin (PCT)
    ICD-10 codes referenced (covered or not-covered mappings shown in policy)ICD-10
    J00 - J06.9Acute upper respiratory infections
    J20.0 - J21.9Acute bronchitis and acute bronchiolitis
    A15.0 - A15.9Respiratory tuberculosis
    B37.0 - B37.9Candidiasis
    C73Malignant neoplasm of thyroid gland
    G00.0 - G00.9Bacterial meningitis, not elsewhere classified
    J12.0 - J12.9Viral pneumonia
    J15.0 - J15.9Bacterial pneumonia
    J18.0 - J18.9Pneumonia, unspecified organism
    J80Acute respiratory distress syndrome
    1–10 of 14
    1/2
    Other CPT codes listed in document related to CPBmixed
    33016 – 33997Surgery; Heart and pericardium (related codes listed)
    35301Thromboendarterectomy, including patch graft, if performed; carotid, vertebral, subclavian, by neck incision
    47533 – 47537Placement of biliary drainage catheter; conversion/exchange/removal of external biliary drainage catheter
    47538 – 47540Placement of stent(s) into a bile duct
    47533Placement of biliary drainage catheter
    48150 – 48154Pancreatectomy, proximal subtotal with total duodenectomy
    No coding provided in these chunksmixed
    No codes listed
    PCT risk thresholds (BRAHMS website)
    High risk (BRAHMS website)>2.0 ng/ml = high risk for progression to severe sepsis/septic shock
    Low risk (BRAHMS website)<0.5 ng/ml = low risk
    Below detection / healthy (BRAHMS website)<0.3 ng/ml = below detection limit / represents healthy condition
    PCT cutoff for pediatric APN
    Pediatric APN cutoff compared>= 0.5 ng/ml and >= 1.0 ng/ml were compared in meta-analysis
    Performance at 0.5 ng/mlPooled sensitivity 0.86, pooled specificity 0.76 (per meta-analysis)
    Performance at 1.0 ng/mlImproved specificity to 0.91 and AUROC 0.94 at 1.0 ng/ml (per meta-analysis)
    PCT diagnostic threshold example (endocarditis study)
    Endocarditis study example threshold0.04 ng/ml (sensitivity 95%, specificity 14%)
    Median PCT in endocarditis vs non-endocarditisMedian 0.21 ng/ml vs 0.13 ng/ml (p < 0.0005)
    Clinical implicationLow threshold yields high sensitivity but very poor specificity; suitable diagnostic cutoff not established
    PCT diagnostic thresholds
    Common diagnostic thresholds referenced0.5 ng/ml; 1.0 ng/ml; 2.0 ng/ml
    Context — pediatric APN0.5 and 1.0 ng/ml evaluated for APN in children (meta-analysis)
    Context — neonatal sepsis2.0 ng/ml evaluated in neonatal sepsis study (performance reported)
    Reported PCT thresholds and cut-points
    Pancreatic necrosis example0.5 ng/ml (day 1) used in one study of pancreatic necrosis
    ICU study blood culture threshold3.61 ng/ml identified as threshold for predicting positive blood culture in one ICU study
    TB prognostic cut-point example>0.13 ng/ml (day 0) reported as mortality predictor in pulmonary TB study
    Trauma prognostic example>=5 ng/ml associated with increased mortality in one trauma study
    Variety of reported cutoffsMultiple studies report diverse cut-points depending on indication, timing, and population

    Provider Actions and Billing Guidance

    Documentation Required

    Authorization and Billing Requirements

    No explicit procedural or billing authorization is stated in the provided policy sections. There are no prior authorization, authorization for billing, coverage pre-authorization, or explicit authorization/denial criteria listed in these document excerpts.

    • No explicit procedural or billing authorization identified in the policy text.
    • No explicit authorization or billing requirements specified in the provided sections.
    • No explicit authorization or coverage requirements specified in the provided sections.
    • No explicit authorization or denial criteria specified in the provided sections.
    Note

    Clinical Evidence and Study Summaries

    Clinical studies, systematic reviews, and meta-analyses summarized in the policy document describe mixed diagnostic performance and clinical utility of PCT across indications. Evidence includes randomized trials of PCT-guided antibiotic discontinuation in ICU and CAP, meta-analyses showing limited sensitivity/specificity for sepsis, assay concordance concerns, and condition-specific meta-analyses (e.g., pediatric APN cut-offs). Clinicians and billing staff should be aware that the policy bases coverage on clinical selection criteria and that the evidence varies by indication.

    • Randomized trials reported reduced antibiotic duration with PCT-guided algorithms in ICU/CAP but had methodological limitations (e.g., per-protocol analyses, algorithm overruling).
    • Meta-analyses show limited diagnostic accuracy for distinguishing sepsis from non-infectious SIRS (sensitivity ~71%, specificity ~71%).
    • Assay concordance between semi-quantitative and quantitative PCT tests can be moderate (kappa ~0.44); laboratory assay type may affect results.
    • Condition-specific evidence varies: pediatric APN shows differing optimal cut-offs (0.5 vs 1.0 ng/mL) with improved specificity at 1.0 ng/mL; neonatal studies show poor sensitivity/specificity for culture-positive sepsis.
    • Systematic reviews for other indications (pancreatic necrosis, surgical infections) conclude evidence is insufficient or heterogeneous.
    • Coverage decisions are tied to the policy’s clinical selection criteria rather than to universal PCT testing for all indications.
    Note

    Policy History and Review Notes

    Policy history and review notes are listed in the document; see policy header for effective date and most recent review. Effective date: 2008-11-21. Last review noted: 2023-10-26. Next review scheduled: 2024-08-22. Review history and definitions links are provided in the source.

    • Effective Date: 2008-11-21
    • Last Review: 10/26/2023
    • Next Review: 08/22/2024
    • Review history and definitions available via referenced links.
    Step Therapy

    Step Therapy / Procedural Actions

    Step therapy or procedural step requirements are not described in the provided policy sections.

    • No step therapy requirements described in the provided document excerpts.
    Documentation Required

    Clinical Indication Documentation

    Provider action: clinical indication documentation — Documentation should support that PCT measurement is being used consistent with the policy’s medical necessity statements (e.g., to initiate or discontinue antibiotics in ICU patients or to guide inpatient respiratory infection management). Claims should include appropriate clinical documentation to demonstrate the covered indication per the policy.

    • Ensure claims and medical records document the specific clinical indication (ICU antibiotic management or inpatient respiratory tract infection) when submitting CPT 84145.
    • Include supporting clinical documentation to justify use per medical necessity criteria.

    Frequency Limits and Testing Cadence

    Procalcitonin (PCT) — Frequency / specification
    Test specification in this sectionNot specified in this section
    FDA-cleared assays referenced elsewhereBRAHMS PCT KRYPTOR, VIDAS BRAHMS PCT, BRAHMS PCT LIA are FDA-cleared quantitative assays (see Definitions)
    Interpretation notePCT should be used in conjunction with other laboratory findings and clinical assessment
    PCT (serial for antibiotic discontinuation algorithms)
    Serial measurements used in RCT antibiotic algorithmAlgorithm used reduction in PCT after 3 days (baseline <1 µg/L) or 5 days (baseline >=1 µg/L) to guide discontinuation
    Reported effectPCT-guided group had shorter median antibiotic duration (6.0 vs 12.5 days) in the trial cited
    Clinical caveatAlgorithm required serial sampling and had instances of physician overruling in trial
    PCT — daily measurements evaluated
    Daily measurements evaluatedDaily PCT measurements were evaluated post-operatively (e.g., days 2–5) in studies of intra-abdominal infection
    Comparative findingCRP outperformed PCT for detection of post-op intra-abdominal infection on day 4 in one study
    No formal payer frequency limitsNo formal frequency limits specified in the policy; studies vary by timing and frequency
    PCT measurements reported at various timepoints
    Reported timepoints in studiesPCT measured at day 1, day 3, day 5 and serially over days in various studies for diagnosis and prognostication
    Use for prognosticationSerial sampling over early hospital days reported in studies predicting outcomes (e.g., TB, trauma, post-cardiac arrest)
    Policy noteThese reported sampling schedules are study-specific and are not established payer frequency rules

    Ordering Requirements

    Documentation Required

    Interpretation and ordering context

    PCT results should be interpreted in conjunction with other laboratory findings and clinical assessments; no explicit provider-type ordering restrictions are provided in these sections.

    • Use PCT as an adjunct to clinical evaluation and other tests rather than as a sole diagnostic criterion.
    • Treating clinicians managing suspected infections or sepsis are the implied ordering providers; the policy does not specify ordering-provider limitations.
    Note

    Ordering considerations

    No explicit ordering restrictions are provided; clinicians ordering PCT should consider assay type and the relevant clinical context when documenting and interpreting results.

    Note

    Ordering provider

    No specific ordering-provider limitations are stated; clinical context in the policy implies ordering by treating clinicians managing suspected infections or sepsis.

    Note

    Ordering settings

    Studies included varied clinical settings (ICU, emergency department, inpatient); the policy provides no explicit ordering-provider restrictions.

    Note

    Ordering requirements (provider identity)

    No explicit ordering provider requirements are provided in these chunks (e.g., who may order is not specified).

    Not Covered / Experimental Uses

    Consistent with the Experimental and Investigational listing, the policy indicates that PCT testing for the many listed indications is not covered because the clinical effectiveness has not been established. Examples included among the investigational/not covered group are neonatal bacterial infection, rhino‑sinusitis, suspected appendicitis, diagnosis of pancreatic necrosis, ventilator‑associated pneumonia, and multiple prognostic and diagnostic uses enumerated in the policy.

    While some document sections do not assert formal non‑coverage lists, the evidence discussion emphasizes that PCT does not add clinically relevant diagnostic information in certain outpatient presentations (for example acute cough/presumed pneumonia in primary care) and that routine use is not supported by the cited literature; therefore many indications remain unsupported by sufficient evidence even if not explicitly enumerated as denied in those chunks.

    Because diagnostic studies for pancreatic necrosis were few and had wide confidence intervals for sensitivity and specificity, the policy concludes that PCT is not supported for diagnosis of pancreatic necrosis and therefore is not recommended for clinical use in that indication.

    The policy highlights that PCT should not be used as a sole diagnostic test to rule out conditions such as peri‑prosthetic joint infection, pancreatic necrosis, candidemia versus bacteremia, or bacterial versus viral community‑acquired pneumonia because current evidence demonstrates inadequate sensitivity and/or specificity for standalone decision‑making.

    The administrative portions of the policy do not present a separate explicit list of denied tests or indications beyond the investigational/experimental section; policy history and review notes are provided without additional denials in the cited chunks.

    Background

    Procalcitonin (PCT) is the pro‑peptide precursor of the hormone calcitonin that rises rapidly in response to bacterial infection and often correlates with severity of systemic infection. FDA‑cleared quantitative assays (e.g., BRAHMS KRYPTOR, VIDAS BRAHMS PCT, BRAHMS PCT LIA) are intended to aid assessment of risk progression to severe sepsis and to support antibiotic stewardship strategies when interpreted alongside clinical assessment and other laboratory data.

    Definitions and Assays

    FDA-cleared PCT assays
    FDA-cleared quantitative assays (examples)BRAHMS PCT sensitive KRYPTOR; VIDAS BRAHMS PCT; BRAHMS PCT LIA
    Assay purposeIntended to aid assessment of risk progression to severe sepsis/septic shock in critically ill patients
    510(k) summaries citedFDA 510(k) summaries are referenced for these assays in the policy references
    Procalcitonin (PCT)
    PCT descriptionA serum biomarker that may be elevated in bacterial infection and sepsis, investigated for diagnostic and antibiotic stewardship applications
    Limitations notedPCT lacks perfect sensitivity/specificity and should be interpreted with clinical context and other labs
    Intended use statement for assaysFDA-cleared assays are intended to be used in conjunction with other laboratory findings and clinical assessments
    Acute pyelonephritis (APN) in pediatrics
    Pediatric APN contextAcute pyelonephritis in infants and children — PCT thresholds of 0.5 ng/ml and 1.0 ng/ml have been evaluated
    Preferred cutoff per meta-analysis1.0 ng/ml produced improved specificity and AUROC compared with 0.5 ng/ml
    Evidence noteMeta-analysis included 18 studies with 831 APN patients
    Procalcitonin (PCT) — definition and utility
    PCT test characteristic summaryPCT is often elevated in bacterial infection but lacks perfect sensitivity and specificity; meta-analyses report moderate pooled performance
    Use with clinical assessmentPCT should not be used alone to rule in or rule out sepsis; results require clinical correlation
    Role in stewardshipRandomized trials suggest PCT guidance can reduce antibiotic exposure in some settings but with limitations
    PCT thresholds (study examples)
    Common study thresholds0.5 ng/ml and 1.0 ng/ml (pediatric APN); 2.0 ng/ml evaluated in neonatal sepsis studies
    Interpretation caveatThreshold choice affects sensitivity/specificity and may vary by population and clinical question
    Assay dependenceDifferent FDA-cleared assays and technologies may yield varying analytic sensitivity and turnaround
    Diagnostic performance metrics
    Performance metrics reportedStudies report sensitivity, specificity, area under the ROC curve (AUC/AUROC), diagnostic odds ratio, and likelihood ratios
    Example pooled performanceMeta-analysis for sepsis found pooled sensitivity ~71% and specificity ~71%
    Example APN metricsPCT >=0.5 ng/ml: sensitivity 0.86, specificity 0.76; PCT >=1.0 ng/ml: specificity 0.91, AUROC 0.94
    FDA 510(k) summaries for PCT assays
    FDA 510(k) documentation referenced510(k) summaries cited for BRAHMS PCT sensitive KRYPTOR (K070310), BRAHMS PCT LIA (K040887), and VIDAS BRAHMS PCT assay (K071146)
    ImplicationThese FDA clearances support the use of named quantitative PCT assay systems referenced in the policy
    Assay-specific detailsDevices utilize different technologies and instruments but share similar intended uses

    Evidence Highlights and Key Studies

    18studies in sepsis meta-analyses
    71%pooled sensitivity (sepsis meta-analyses)
    831pediatric APN patients pooled
    12CAP studies pooled
    1,065patients in cardiac-arrest prognostic meta-analysis

    inv-04: Evidence summaries (redundant grouping for detailed evidence mapping)

    Detailed evidence summaries for clinician reference:

    Sepsis accuracy and trials: An evidence synthesis and meta‑analyses report PCT discriminates sepsis from non‑infectious inflammation poorly (sensitivity and specificity ~71%); randomized trials of PCT‑guided therapy did not demonstrate mortality benefit though some showed reduced antibiotic exposure; trial limitations include exclusions, per‑protocol analyses, and algorithm overruling.sensitivity ~71%, specificity ~71%

    Tang et al (2007); Nobre et al (2008); UpToDate summary.

    Pediatric APN and neonatal findings: Pediatric meta‑analysis supports PCT cutoffs (0.5 and 1.0 ng/ml) with improved specificity at 1.0 ng/ml for APN; neonatal prospective study found limited sensitivity and specificity at 2 ng/ml for culture‑positive sepsis.APN: 0.5 vs 1.0 ng/ml; neonatal: 2 ng/ml

    Zhang et al (2016); Chaurasia et al (2023).

    CAP prognostic association: PCT at presentation correlates with risk of needing invasive respiratory/vasopressor support and improves prediction when added to severity scores in hospitalized CAP patients.per 1 ng/ml -> ~1–2% IRVS risk

    Self et al (2016).

    Post‑operative IAI and CRP comparison: Studies and meta‑analyses in elective colorectal surgery report CRP often outperforms or provides similar predictive accuracy to PCT for postoperative intra‑abdominal infection; PCT did not add clinical value to CRP for early discharge decision in some analyses.post‑op day 3–5 comparisons

    Facy et al (2016); Cousin et al (2016).

    inv-05: Indication-specific evidence summaries (redundant grouping for detailed evidence mapping)

    More granular, indication‑specific evidence mapping:

    Pancreatic necrosis: Limited diagnostic studies with heterogeneous timing and thresholds produced wide confidence intervals; reviewers concluded PCT (and other tests) were not sufficiently accurate for clinical practice and further rigorous studies are required.

    Cochrane review (3 studies, 242 participants).

    Peri‑prosthetic joint infection (PJI): Meta‑analysis comparing IL‑6 and PCT (18 studies) found IL‑6 superior for rule‑out performance while PCT had high specificity and positive LR, supporting adjunctive rule‑in use only.

    Yoon et al (2018).

    Candidemia vs bacteremia: Systematic review (16 studies) found lower PCT in candidemia versus bacteremia but insufficient discrimination and heterogeneous, mostly retrospective data; not suitable as a standalone diagnostic test.

    Cortegiani et al (2019).

    Revision History

    2008-11-21Policy effective

    Policy became effective on November 21, 2008.

    2023-10-26Policy reviewLatest

    Policy was last reviewed on October 26, 2023.

    2024-08-22Next scheduled review

    Next scheduled policy review date is August 22, 2024.

    Differential bacteremia vs candidemia: Systematic review found lower PCT in candidemia versus bacteremia but evidence is heterogeneous and insufficient to use PCT alone for differentiation; adjunctive use with other biomarkers may improve discrimination.

    Cortegiani et al (2019).

    CAP diagnostic accuracy: Meta‑analysis (12 studies, 2,408 patients) reported sensitivity 0.55 and specificity 0.76 for distinguishing bacterial from viral CAP, concluding PCT is unlikely to reliably determine need for antibiotics in CAP on its own.

    Kamat et al (2020).

    Post‑cardiac arrest prognostication: Systematic review/meta‑analysis (10 studies, 1,065 patients) associated elevated PCT within 0–48 hours post‑cardiac arrest with higher in‑hospital mortality and poor neurologic outcomes, suggesting potential prognostic value pending validation.

    Shin et al (2019).